Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody

Cell Rep. 2014 Jul 24;8(2):410-9. doi: 10.1016/j.celrep.2014.06.038. Epub 2014 Jul 17.

Abstract

Interleukin-3 (IL-3) is an activated T cell product that bridges innate and adaptive immunity and contributes to several immunopathologies. Here, we report the crystal structure of the IL-3 receptor α chain (IL3Rα) in complex with the anti-leukemia antibody CSL362 that reveals the N-terminal domain (NTD), a domain also present in the granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-5, and IL-13 receptors, adopting unique "open" and classical "closed" conformations. Although extensive mutational analyses of the NTD epitope of CSL362 show minor overlap with the IL-3 binding site, CSL362 only inhibits IL-3 binding to the closed conformation, indicating alternative mechanisms for blocking IL-3 signaling. Significantly, whereas "open-like" IL3Rα mutants can simultaneously bind IL-3 and CSL362, CSL362 still prevents the assembly of a higher-order IL-3 receptor-signaling complex. The discovery of open forms of cytokine receptors provides the framework for development of potent antibodies that can achieve a "double hit" cytokine receptor blockade.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibodies, Monoclonal, Humanized / chemistry*
  • Antibodies, Monoclonal, Humanized / immunology
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / metabolism
  • Binding Sites, Antibody
  • COS Cells
  • Chlorocebus aethiops
  • HEK293 Cells
  • Humans
  • Interleukin-3 Receptor alpha Subunit / chemistry*
  • Interleukin-3 Receptor alpha Subunit / immunology
  • Molecular Sequence Data
  • Protein Binding

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • IL3RA protein, human
  • Interleukin-3 Receptor alpha Subunit

Associated data

  • PDB/4JZJ